Cargando…
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
Background Concurrent chemoradiotherapy is the standard of care for locally advanced cervical cancer. Concurrent chemoradiotherapy with programmed blockade of the cell death-1/programmed cell death-ligand 1 pathway may promote a more immunogenic environment through increased phagocytosis, cell death...
Autores principales: | Mayadev, Jyoti, Nunes, Ana T, Li, Mary, Marcovitz, Michelle, Lanasa, Mark C, Monk, Bradley J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398223/ https://www.ncbi.nlm.nih.gov/pubmed/32447296 http://dx.doi.org/10.1136/ijgc-2019-001135 |
Ejemplares similares
-
Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020) -
Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
por: Kadkhodayan, Sima, et al.
Publicado: (2013) -
Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis
por: Liu, Haonan, et al.
Publicado: (2022) -
Comparison of Induction Chemotherapy Plus Concurrent
Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced
Nasopharyngeal Carcinoma
por: Xu, Guoqiang, et al.
Publicado: (2021) -
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)